-

Cell Counting Market by Product, Consumables, Cancer, Stem Cell Research, End User - Global Forecast to 2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell Counting Market by Product (Instruments (Spectrophotometer, Hemocytometer, Flow Cytometer, Hematology Analyzers), Consumables (Reagent, Microplate)), Cancer, Stem Cell Research, End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global cell counting market is estimated to reach USD 14.50 billion by 2025 from USD 10.49 billion in 2020, at a CAGR of 6.7% during the forecast period.

Market growth is largely driven by growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematology analyzers. On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.

The research application segment commanded the largest share of the market in 2019.

On the basis of application, the cell counting market is segmented into research, medical, and industrial applications. In 2019, research applications accounted for the largest share of the market. Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment.

The research institutes segment commanded the largest share of the cell counting market in 2019.

On the basis of end-users, the cell counting market is segmented into research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and CROs, and other end users. In 2019, research institutes accounted for the largest share of the market. The large share of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies.

The Asia Pacific region to register the highest growth in the global cell count market during the forecast period.

The Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization are supporting market growth in the Asia Pacific.

Market Dynamics

Drivers

  • Funding for Cell-Based Research
  • Rising Incidence of Chronic and Infectious Diseases
  • Growing Biotechnology and Biopharmaceutical Industries
  • Development of Enhanced Solutions and Improved Image Analysis
  • Growing Use of High-Throughput Flow Cytometry and Automated Hematology Analyzers

Restraints

  • High Cost of Cell Analysis Instruments

Opportunities

  • Applications of Cell Counting in Personalized Medicine
  • Growth in Stem Cell Research

Challenges

  • Dearth of Skilled Professionals in Clinical Laboratories

Company Profiles

  • Danaher Corporation
  • Thermo Fisher Scientific
  • Becton, Dickinson and Company
  • Merck Kgaa
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Perkinelmer, Inc.
  • Agilent Technologies, Inc.
  • Corning
  • Tecan
  • Boule Diagnostics Ab
  • Olympus Corporation
  • Horiba
  • Sysmex Corporation
  • Siemens Healthineers Ag
  • F. Hoffmann-La Roche Ag
  • Luminex Corporation
  • Nexcelom Bioscience Llc
  • Tip Biosystems
  • Logos Biosystems, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/dlqdqr

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Blockchain and Non-Fungible Tokens new Technologies and the Relevant Law Training Course: Core Principles, Smart Contracts, NFTs, and Decentralized Finance Explained (Online Event: May 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blockchain and Non-Fungible Tokens: Understanding new Technologies and the Relevant Law Training Course (May 20, 2026)" training has been added to ResearchAndMarkets.com's offering. Blockchain is a new technology that could potentially have major impacts in a wide range of industries. It has the potential to dramatically change how business is conducted - but there is no one central authority controlling blockchain, everyone has access to the same information. Are...

Writing Clinical Research with Integrity Training Course: Principles of Medical and Scientific Writing, Including Ethical Standards, Data Integrity, and Plagiarism Prevention (Online: Apr 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course covers key principles of medical and scientific writing, including ethical standards, data integrity, and plagiarism prevention. Participants will learn how to tailor content for various audiences, structure documents (e.g., manuscripts, protocols), and adhere to writing standards such as clarity, consistency, and correc...

In-Vitro Diagnostic Regulation (EU) 2017/746 Introduction Training Course (Online Event: Apr 16th - Apr 17th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course (Apr 16th - Apr 17th, 2026)" training has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The Regulation in...
Back to Newsroom